This is the big gamble - Celebrex generic is already in market - so who will really be interested in going against generics with known thin margins?
So chance of immediate collaboration or BO is low - KTOV is so small that they cannot market the product.
One possibility I see is - TEVA already has approval to sell generic Celebrex in US since 2014 - they may like to buy this product license and combine as a variant of Celebrex for sub-population. This and Israeli connection can help KTOV to cut a deal - however with Teva’s problems - not sure we can expect any significant deal.
The co market cap is $28 million - so Teva can buy them out at just 56 to $84 million (really cheap) to take out competition. That will give 2 to 2.5 times current price - I will be more than happy to come out at that price.
News 
Market Data 
Discover 
